Commentary: SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China

Otros/as autores/as

Institut Català de la Salut

[Di Cosimo S] Biomarker Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy. [Porcu L] Laboratory of Methodology for Clinical Research, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy. [Malfettone A] Medica Scientia Innovation Research (MedSIR), New Jersey, United States. [Cortés J] Medica Scientia Innovation Research (MedSIR), New Jersey, United States. Medica Scientia Innovation Research (MedSIR), Barcelona, Spain. IOB Institute of Oncology, Quiron Group, Madrid, Spain. IOB Institute of Oncology, Quiron Group, Barcelona, Spain. Vall d'Hebron Insititute of Oncology (VHIO), Barcelona, Spain. [Miceli R] Clinical Epidemiology and Trial Organization Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy

Vall d'Hebron Barcelona Hospital Campus

Fecha de publicación

2021-09-10T10:06:39Z

2021-09-10T10:06:39Z

2020-07-10



Resumen

COVID-19; Atenció al càncer; Orientació del pacient


COVID-19; Cuidado del cáncer; Orientación al paciente


COVID-19; Cancer care; Patient guidance


A Commentary on: SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China. By Yu, J., Ouyang, W., Chua, M. L. K., and Xie, C. (2020). JAMA Oncol. doi: 10.1001/jamaoncol.2020.0980:ca_ES

Tipo de documento

Artículo


Versión publicada

Lengua

Inglés

Publicado por

Frontiers Media

Documentos relacionados

Frontiers in Oncology;10

https://doi.org/10.3389/fonc.2020.01223

Citación recomendada

Esta citación se ha generado automáticamente.

Derechos

Attribution 4.0 International

http://creativecommons.org/licenses/by/4.0/

Este ítem aparece en la(s) siguiente(s) colección(ones)